• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

    5/18/26 11:59:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem.

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $300 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on May 21, 2026, subject to customary closing conditions. Hims & Hers also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of notes.

    Hims & Hers intends to use the net proceeds from the offering to preserve financial flexibility while executing on its international expansion strategy, including its proposed acquisition of Eucalyptus, which is expected to close in mid-2026, subject to customary closing conditions. The Company also intends to use the net proceeds to invest in technology and fulfillment infrastructure to drive anticipated cost efficiencies, as well as to scale AI capabilities that enhance the consumer experience and better leverage the Company's closed-loop data ecosystem. A portion of the net proceeds will be used to fund the cost of entering into the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, a portion of the additional proceeds will also be used to fund the cost of entering into the related capped call transactions. The Company intends to use the remainder of the net proceeds, if any, for general corporate purposes.

    The notes will be senior, unsecured obligations of Hims & Hers. The notes will not bear regular interest, and the principal amount of the notes will not accrete. The notes will mature on June 1, 2032, unless earlier repurchased, redeemed or converted. Before March 1, 2032, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after March 1, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Hims & Hers will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at the Company's option. The initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $29.53 per share of Class A common stock. The initial conversion price represents a premium of approximately 32.5% over the last reported sale price of $22.29 per share of the Company's Class A common stock on May 18, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

    The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Company's option at any time, and from time to time, on or after June 6, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of the Company's Class A common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date.

    If a "fundamental change" (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Hims & Hers to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid special and additional interest, if any, to, but excluding, the applicable repurchase date.

    Hims & Hers estimates that the net proceeds from the offering will be approximately $338.5 million (or approximately $389.5 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers' discounts and commissions and the Company's estimated offering expenses. Hims & Hers intends to use approximately $32.0 million of the net proceeds to fund the cost of entering into the capped call transactions described below.

    In connection with the pricing of the notes, Hims & Hers entered into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or one or more other financial institutions (the "option counterparties"). The capped call transactions are expected generally to reduce the potential dilution to the Company's Class A common stock upon any conversion of the notes and/or offset any potential cash payments Hims & Hers is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap.

    The cap price of the capped call transactions will initially be approximately $50.15 per share, which represents a premium of approximately 125% over the last reported sale price of the Company's Class A common stock of $22.29 per share on May 18, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

    If the initial purchasers exercise their option to purchase additional notes, then Hims & Hers expects to enter into additional capped call transactions with the option counterparties. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to the Company's Class A common stock and/or purchase shares of the Company's Class A common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company's Class A common stock or the notes at that time.

    In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company's Class A common stock and/or purchasing or selling the Company's Class A common stock or other securities of Hims & Hers in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so (x) during any observation period related to a conversion of notes or following any repurchase of notes by Hims & Hers in connection with any redemption or fundamental change or (y) following any other repurchase of notes by the Company if the Company elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or decrease in the market price of the Company's Class A common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes.

    The offer and sale of the notes and any shares of Class A common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Class A common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

    About Hims & Hers

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    Forward-Looking Statements

    Except for historical information, certain statements in this press release, including statements regarding the completion of the offering, the expected amount and intended use of the net proceeds, the timing of the closing of the proposed Eucalyptus transaction, and the effects of entering into the capped call transactions described above, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business, including, without limitation, risks and uncertainties related to market conditions, the satisfaction of the closing conditions related to the offering, risks related to obtaining the requisite consents to the proposed Eucalyptus transaction, including, without limitation, the timing (including possible delays) and receipt of regulatory approvals from governmental entities (including any conditions, limitations or restrictions placed on these approvals) and the risk that one or more governmental entities may deny approval, and risks relating to international expansion and the Company's business and strategy. Hims & Hers may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Hims & Hers does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the "Risk Factors" section in the Company's most recently filed Quarterly Report on Form 10-Q and its most recently filed Annual Report on Form 10-K.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260518180060/en/

    Investor Relations

    Bill Newby

    Investors@forhims.com

    Media Relations

    Abby Reisinger-Moley

    Press@forhims.com

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    5/12/2026$30.00 → $35.00Buy
    Needham
    4/24/2026$35.00Overweight
    Analyst
    3/10/2026$24.00Sell → Neutral
    Citigroup
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    3/9/2026$30.00Hold → Buy
    Needham
    2/24/2026Buy → Neutral
    BTIG Research
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Medical Officer Carroll Patrick Harrison

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:21 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Wells David B

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:05 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

    Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advan

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

    Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper's comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/Closing brings world-class technology and clinical infrastructu

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform

    The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE:HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, af

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    6/2/26 6:02:26 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/21/26 5:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/19/26 8:17:31 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

    Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings rele

    5/11/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management

    4/13/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company's 2026 annual shareholder meeting in June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise. Amoo-Gottfried is a seasoned marketing l

    4/28/26 8:35:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00 from $30.00 previously

    5/12/26 10:08:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Hims & Hers Health with a new price target

    Analyst initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $35.00

    4/24/26 8:05:39 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care